23953-39-1

Basic information

• Product Name: MBX-102/JNJ39659100
• Synonyms: (aR)-4-chloro-a-[3-(trifluoromethyl)phenoxy]benzeneacetic acid;MBX-102 acid;MBX-102/JNJ39659100
• CAS NO: 23953-39-1
• Molecular Formula: C15H10ClF3O3
• Molecular Weight: 330.691
• Mol File: 23953-39-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: MBX-102/JNJ39659100(CAS DataBase Reference)
• NIST Chemistry Reference: MBX-102/JNJ39659100(23953-39-1)
• EPA Substance Registry System: MBX-102/JNJ39659100(23953-39-1)

Safety Data

• Hazardous Substances Data: 23953-39-1(Hazardous Substances Data)

Upstream product

• 930779-79-6 (2S)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl 2-bromo-2-(4-chlorophenyl)acetate 
• 1190112-06-1 C₇H₄F₃O^(1-)*Li⁽¹⁺⁾ 
• 1878-66-6 4-chlorophenylacetic Acid 
• 25026-34-0 4-chlorophenacetyl chloride 
• 52574-79-5 α-bromo-p-chlorophenylacetic acid chloride 
• 4687-08-5 halofenic acid 
• 98-17-9 3-Trifluoromethylphenol 
• 32174-34-8 methyl 4-chloromandelate 
• 186025-92-3 methyl 4-chloro-α-(methanesulfonyloxy)phenylacetate 
• 4925-90-0 methyl 4-chloro-α-(3-trifluoromethylphenoxy)phenylacetate 

Downstream Products

• 24136-23-0 Arhalofenate 
• 1190305-31-7 C₁₅H₉Cl₂F₃O₂ 

Relevant articles and documents

On the metabolically active form of metaglidasen: Improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles

Metaglidasen is a fibrate-like drug reported as a selective modulator of peroxisome proliferator-activated receptor γ (PPARγ), able to lower plasma glucose levels in the absence of the side effects typically observed with thiazolidinedione antidiabetic agents in current use. Herein we report an improved synthesis of metaglidasen's metabolically active form halofenic acid (R)-2 and that of its enantiomer (S)-2. The activity of the two stereoisomers was carefully examined on PPARα and PPARγ subtypes. As expected, both showed partial agonist activity toward PPARγ; the investigation of PPARα activity, however, led to unexpected results. In particular, (S)-2 was found to act as a partial agonist, whereas (R)-2 behaved as an antagonist. X-ray crystallographic studies with PPARγ were carried out to gain more insight on the molecular-level interactions and to propose a binding mode. Given the adverse effects provoked by fibrate drugs on skeletal muscle function, we also investigated the capacity of (R)-2 and (S)-2 to block conductance of the skeletal muscle membrane chloride channel. The results showed a more beneficial profile for (R)-2, the activity of which on skeletal muscle function, however, should not be overlooked in the ongoing clinical trials studying its long-term effects.

Compositions and methods for the treatment of metabolic syndrome

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of fo

PROCESS FOR THE PREPARATION OF (-)-(4-CHLORO-PHENYL)-(3-TRIFLUOROMETHYL-PHENOXY)-ACETIC ACID 2-ACETYLAMINO-ETHYL ESTER

The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-thfluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-thfluoromethyl-phenoxy)-acetic acid, a synthesis intermediate.